Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of M-001 Followed by IIV4 in Healthy Adults
NCT03058692Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2018
- Primary completion
- Jan 2019
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza comparing M-001 + IIV4 with Placebo + IIV4 (2 arms). Primary endpoints: Mean Percentage of Perforin+ CD4+ and CD8+ T Cells After Stimulation With M-001 Component Peptides, Mean Percentage of CD107a+ CD4+ and CD8+ T Cells After Stimulation With M-001 Component Peptides and 7 more. Started Apr 2018; status: completed.
02
Drugs
multimeric-001
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03058692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058692.